At the Annual General Meeting in LEO Holding A/S on February 26th a unified Board of Directors elected former vice chairman Olivier Bohuon as new chairman of the Board of Directors of LEO Pharma following Jukka Pertola’s decision to leave the Board. Anders Ekblom was elected as new vice chairman. In addition, John Weeks decided to not seek re-election.
“With Olivier Bohuon and Anders Ekblom we have two strong successors with extensive industry experience who can help set the direction for LEO Pharma’s future development and realize the company’s ambitious strategy towards 2025. Olivier Bohuon has profound knowledge from several leading posi-tions in the global pharma industry and Anders Ekblom’s scientific background and comprehensive experience from the global life science sector is an ideal complement”, said Jukka Pertola, resigning chairman of LEO Pharma.
Jukka Pertola has been member of LEO Pharma’s Board of Directors since 2011 and chairman since 2016.
“Jukka Pertola has been instrumental in getting LEO Pharma to the position the company holds today and by manning the board with strong profiles and securing board succession. During his time as member and chairman of the Board of Directors, LEO Pharma has gone through a massive transformation turning the company into a global leader specialized in medical dermatology. I would like to express my sincere gratitude to Jukka for his contribution”, said Lars Olsen, chairman of the Board of Trustees of the LEO Foundation, also thanking John Weeks for his dedicated contribution as member of the Board of Directors at LEO Pharma since 2014.
Olivier Bohuon is External Director of the Board of Directors at Takeda plc, External Director of the Board of Directors of Smiths Group plc, a supervisory board member at Virbac SA, and member of the French National Pharmacy Academy and the French Academy of Technologies. From 2011 to May 2018 Bohuon served as CEO of medical equipment specialist Smith & Nephew Plc. Before that, he held positions as CEO at Laboratories Pierre Fabre and President of Pharmaceutical Products Division at Abbott Laboratories.
Anders Ekblom is a physician, board certified in anaesthesia and intensive care, dentist and Associate Professor in physiology at Karolinska Institute and a fellow of the Royal Swedish Academy of Engineering Sciences. His experience from the global biopharmaceutical industry includes positions as EVP Global Medicines Development at AstraZeneca Plc, CEO of AstraZeneca AB Sweden, Director of the Board at Mereo BioPharma Group Plc, Alligator Bioscience AB, and several other companies.